InspireMD, Inc. (NSPR)
Automate Your Wheel Strategy on NSPR
With Tiblio's Option Bot, you can configure your own wheel strategy including NSPR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NSPR
- Rev/Share 0.1676
- Book/Share 0.8517
- PB 3.698
- Debt/Equity 0.0578
- CurrentRatio 4.3632
- ROIC -1.171
- MktCap 76588250.0
- FreeCF/Share -0.6478
- PFCF -2.8197
- PE -4.2474
- Debt/Assets 0.0424
- DivYield 0
- ROE -0.6471
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
InspireMD, Inc. (NSPR) Q1 2025 Earnings Call Transcript
Published: May 09, 2025 by: Seeking Alpha
Sentiment: Neutral
InspireMD, Inc. (NASDAQ:NSPR ) Q1 2025 Earnings Conference Call May 9, 2025 8:30 AM ET Company Participants Webb Campbell – Gilmartin Group LLC Marvin Slosman – Chief Executive Officer Craig Shore – Chief Financial Officer Shane Gleason – Chief Commercial Officer Conference Call Participants Adam Maeder – Piper Sandler Frank Takkinen – Lake Street Capital Operator Good morning, and welcome to InspireMD's First Quarter 2025 Earnings Conference call. [Operator Instructions] We will facilitating a question-and-answer session towards the end of today's call.
Read More
InspireMD, Inc. (NSPR) Reports Q1 Loss, Tops Revenue Estimates
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Negative
InspireMD, Inc. (NSPR) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.21 per share a year ago.
Read More
InspireMD Reports First Quarter 2025 Financial Results
Published: May 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
Management to host investor conference call today, May 9th, at 8:30am ET Management to host investor conference call today, May 9th, at 8:30am ET
Read More
InspireMD to Announce First Quarter 2025 Financial Results
Published: April 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
MIAMI, April 25, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease (CAD) and prevention of stroke, today announced that it will release its first quarter 2025 financial results on Friday, May 9, 2025. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights.
Read More
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: April 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
MIAMI, April 08, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD's Board of Directors approved inducement grants to 11 new non-executive employees in the aggregate amount of 299,398 shares of restricted stock (the “Inducement Grants”) outside of InspireMD's 2021 Equity Compensation Plan, with a grant date as of April 1, 2025, as an inducement material to the employees and the director entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4).
Read More
InspireMD to Present at Upcoming 24th Annual Needham Virtual Healthcare Conference
Published: March 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
MIAMI, March 26, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced management will present at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025, at 8:00AM Eastern Time / 5:00AM Pacific Time. A live audio webcast and replay of the presentation may be accessed for 90 days on the “News & Events” section of the company's website at: https://www.inspiremd.com/en/events/ About InspireMD, Inc. InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry …
Read More
InspireMD, Inc. (NSPR) Q4 2024 Earnings Call Transcript
Published: March 12, 2025 by: Seeking Alpha
Sentiment: Neutral
NSPR (NASDAQ:NSPR ) Q4 2024 Earnings Conference Call March 12, 2025 8:30 AM ET Company Participants Marvin Slosman - CEO Craig Shore - CFO Shane Gleason - CCO Webb Campbell - IR, Gilmartin Group Conference Call Participants Adam Maeder - Piper Sandler Frank Takkinen - Lake Street Capital Markets Richard Nesbitt - InspireMD Operator Hello and welcome to InspireMD's fourth quarter 2024 earnings conference call. [Operator instructions].
Read More
InspireMD, Inc. (NSPR) Reports Q4 Loss, Tops Revenue Estimates
Published: March 12, 2025 by: Zacks Investment Research
Sentiment: Neutral
InspireMD, Inc. (NSPR) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.16 per share a year ago.
Read More
InspireMD to Announce Fourth Quarter and Full Year 2024 Financial Results
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
MIAMI, Feb. 26, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease (CAD) and prevention of stroke, today announced that it will release its fourth quarter and full year 2024 financial results on Wednesday, March 12, 2025. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m.
Read More
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
MIAMI, Feb. 25, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD's Board of Directors approved inducement grants to six new non-executive employees in the aggregate amount of 138,442 shares of restricted stock outside of InspireMD's 2021 Equity Compensation Plan, with a grant date as of February 5, 2025, as an inducement material to the employees and the director entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement plan is used exclusively for the grant …
Read More
InspireMD and NAMSA to Partner on CGUARDIANS II Pivotal Clinical Trial of the CGuard Prime™ 80 cm Carotid Stent System for Use in TCAR procedures
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
TOLEDO, Ohio and MIAMI, Feb. 13, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime Carotid Stent System for the prevention of stroke related to carotid stenosis, and NAMSA, a world-leading MedTech Contract Research Organization (CRO) offering global end-to-end development services, today announced that, pursuant to a previously announced strategic outsourcing partnership, the companies are working together to conduct the CGUARDIANS II pivotal study of InspireMD's CGuard Prime™ 80 cm carotid stent system for use in Transcarotid Artery Revascularization (TCAR) procedures.
Read More
About InspireMD, Inc. (NSPR)
- IPO Date 2011-04-12
- Website https://www.inspiremd.com
- Industry Medical - Devices
- CEO Mr. Marvin L. Slosman
- Employees 85